Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the triple co administration of albendazole, ivermectin and azithromycine is as safe as the current treatment scheme that consists to treat with albendazole plus ivermectin together and a week later to treat with azithromycin in areas co endemic for lymphatic filariasis and trachoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre d'Appui à la lutte contre la Maladie
• Collaborator: International Trachoma Initiative
• Treatments: Albendazole; Azithromycin; Ivermectin

Criteria

Inclusion Criteria:

• Must have been residing in the village for at least three months;

• Must be 90 cm tall or more;

• Must be between 5 years and 65 years of age;

• Must not be pregnant;

• Must not be lactating.

Exclusion Criteria:

• Subjects under 5 years of age or less than 90 cm in height;

• Subjects over 65 years of age;

• Subjects who cannot swallow tablets;

• Subjects who are sick and bedridden;

• Pregnant women (clinical appreciation in the study);

• Lactating women;

• History of allergies to the drugs being studied (azithromycin, ivermectin, albendazole).